Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11295103 | 0.85 | CYP2C19 (0.41) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30977513 | 0.82 | HTT (0.43) | NR3C1KDM4ESMN1; SMN2CYP2C19HTT | |
| SCHEMBL30977496 | 0.80 | APLNR (0.40) | TSHRNR3C1ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL12930943 | 0.79 | TMEM97 (0.42) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1907350 | 0.79 | GBA1 (0.41) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL856088 | 0.79 | NR3C1 (0.47) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12982419 | 0.77 | CYP2C19 (0.50) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2586556 | 0.74 | NR3C1 (0.46) | TSHRNR3C1KDM4EALDH1A1CYP2C19 | |
| SCHEMBL26977567 | 0.73 | SMN1; SMN2 (0.41) | TSHRKDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL15384643 | 0.72 | NR3C1 (0.49) | TSHRNR3C1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| EP-2665727-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097684-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | TSHR 3258/4885NR3C1 1479/4885KDM4E 838/4885 |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ALK, BRAF, BMX | TSHR 1119/4885NR3C1 1974/4885KDM4E 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.